New Delhi, Dec 06, 2011: Venus Remedies, a research-based global pharmaceutical company, has emerged as a winner of 'Silver Certificate of Merit' in the Economic Times' India Manufacturing Excellence Awards (IMEA) 2011 held in Mumbai. The Chandigarh-based company has bagged this award for its Baddi unit, based on the assessments conducted at the site and whetted by the jury of Economic Times' IMEA 2011 in partnership with Frost & Sullivan.
On winning this prestigious award, Mr Ashutosh Jain, executive director, Venus Remedies, said, "This award is recognition and acknowledgement of our high standards in terms of our manufacturing practices, quality, regulatory approvals, significant investment on our state-of-the-art R&D centre, well equipped facilities and fine infrastructure. It is an endorsement to our continuous endeavor in building Venus Remedies and making it stand amongst the top pharma giants of the industry."
IMEA acknowledges the best facilities in India that have achieved and sustained manufacturing excellence by recognizing the Indian manufacturing capabilities and assessing the global competitiveness. This award celebrates success stories and honor entrepreneurs who have dedication, perseverance, foresight and diligence to develop a successful manufacturing organization and sustain continuous learning.
Out of 103 shortlisted companies, 35 were conferred with this prestigious award under various categories. Besides this, Venus Remedies has recently won the prestigious League of American Communications Professionals Global Communications Competition, the '2011 Spotlight Awards' for its annual report and also bagged 'Patent Award' in Gold category by the Pharmaceuticals Export Promotion Council (Pharmexcil).
Venus Remedies is BSE & NSE listed company with turnover of 357 crores (FY 2011) is present in 60 regulated and semi-regulated countries, actively exporting to more than 20 countries.
The company has two manufacturing locations in India and one in Germany. Venus is top class manufacturer of Oncological and Cephalosporin Injectable products following EU-GMP norms for all is activities. It has 11 overseas offices, 1 R&D center and competent staff of more than 1500 employees. VMRC is the R & D wing of Venus Remedies Limited, approved by Department of Scientific & Industrial Research (DSIR), Govt. of India. VMRC is recognised for development of globally competitive Technologies of high commercial potential.